860 Salvage treatment for vaginal recurrence of endometrial cancer using image-guided adaptive brachytherapy

This is the authors' abstract. We don't add key points for this paper.

Introduction/Background To evaluate local control (LC), locoregional control (LRC), distant control (DC) and overall survival (OS) for patients with vaginal recurrence of endometrial cancer (EC) receiving salvage radiotherapy with image-guided adaptive brachytherapy (IGABT) +/- external beam radiotherapy (EBRT). Methodology We retrospectively evaluated all consecutive patients treated with curative intent with IGABT +/- EBRT for vaginal recurrence of EC at our department between 2001 and 2020. Patients with superficial recurrences (tumour ≤ 7 mm) were treated with IGABT alone. Patients with more advanced tumours received pelvic EBRT + IGABT. Actuarial LC, LRC, DC and OS were calculated using the Kaplan-Meier method; long-term G3–5 toxicity was recorded (CTCAE v5 criteria). Results We identified 46 patients. Radiotherapy for recurrence consisted of IGABT alone for 15 patients and EBRT+IGABT for 31 patients. Three patients received concurrent or sequential platinum-based chemotherapy. Median follow-up for survival was 61 months for the entire cohort. OS was 76.5% at 5 years. Median follow-up for disease control was 41 months. LC, LRC and DC at 5 years were 92.0%, 83.7% and 81.4%, respectively. Maximum toxicity was G3 and occurred in 9 patients. Survival and disease control outcome based on treatment type is shown in table 1. Conclusion IGABT +/- EBRT can effectively salvage vaginal recurrences of EC with acceptable toxicity rates. Disclosures The authors have no conflicts of interest to disclose.